HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Acotec Scientific Holdings (6669.HK) - The Company Is Now In Trouble

Zylox-Tonbridge Medical Technology (2190.HK) - A Good Alpha-Generating Opportunity for Investors

Pre-IPO MIXUE Group - The Snow King Opens up a Lot More Room for Imagination than Expected

Acotec Scientific (6669.HK) - What Value Boston Scientific Will Bring Is Crucial to Future Valuation

Acotec Scientific (6669.HK) - Growth Is Expected to Continue, But Risks Behind Can't Be Ignored

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Escalation of Israel-Hamas War - Here's How Investors Should Position Themselves in Dramatic Changes

Equity Bottom-Up

Acotec Scientific Holdings / Equity Bottom-Up

<ul>
<li>After 23H1 results were released, we have seen some positive business progress in internationalization. There has been no obvious negative news about performance. Acotec's future prospects are still relatively optimistic.</li>
<li>Contrary to solid fundamentals, Acotec's stock price continues to decline. The sluggish stock price performance is not directly related to fundamentals, but rather to poor liquidity and unsatisfactory capital inflows.</li>
<li>Stock price hasn’t bottomed yet, so investors're not advised to rush to buy the dip.For market value management, Acotec's management need to invest more energy/time to maximize shareholder value/investors’ returns.</li>
</ul>


After 23H1 results were released, we have seen some positive business progress in internationalization. There has been no obvious negative news about performance. Acotec's future prospects are still relatively optimistic.
Contrary to solid fundamentals, Acotec's stock price continues to decline. The sluggish stock price performance is not directly related to fundamentals, but rather to poor liquidity and unsatisfactory capital inflows.
Stock price hasn’t bottomed yet, so investors're not advised to rush to buy the dip.For market value management, Acotec's management need to invest more energy/time to maximize shareholder value/investors’ returns.


Acotec Scientific Holdings (6669.HK) - The Fall in Share Price Is Not over Yet